Company / Net Income
ALNYLAM PHARMACEUTICALS, INC. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$18.3M
FY2025
5-year range
-$886.1M / -$18.3M
FY2021-FY2025
Trend
+93.4%
vs FY2024
Sector context
#71 of 216
Health Care
What the data says
At -$18M, ALNYLAM PHARMACEUTICALS, INC.'s net income ranks #71 of 216 in the Health Care sector. Net Income has increased for 4 consecutive years, from -$886M in FY2021 to -$18M in FY2025.
Based on SEC 10-K filings.
-$18M in FY2025.
Improved from -$440M to -$18M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#71 of 216 in Health CareTop 33% of 216This company -$18.3M Sector average $454.1M
▼
-104.0% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s net income has grown for 4 consecutive years.
- In FY2025, net income increased 93.4% year-over-year.
- Ranks #71 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$18.3M | +93.4% |
| FY2024 | -$278.2M | +36.8% |
| FY2023 | -$440.2M | +48.7% |
| FY2022 | -$858.3M | +3.1% |
| FY2021 | -$886.1M | -16.4% |
| FY2020 | -$761.5M | -55.1% |
| FY2019 | -$490.9M | -19.7% |
| FY2018 | -$410.1M | +16.5% |
| FY2017 | -$490.9M | -19.7% |
| FY2016 | -$410.1M | -41.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026